F. Hoffmann-La Roche AG Switzerland
Research
Date range: 1 May 2021 - 30 April 2022
Region: Global
Subject/journal group: All
The table to the right includes counts of all research outputs for F. Hoffmann-La Roche AG published between 1 May 2021 - 30 April 2022 which are tracked by the Nature Index.
Hover over the donut graph to view the Share for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.
Note: Articles may be assigned to more than one subject area.
Count | Share |
---|---|
132 | 47.14 |
Outputs by subject (Share)
Subject | Count | Share |
---|---|---|
Life Sciences | 107 | 33.84 |
Chemistry | 27 | 14.09 |
Earth & Environmental Sciences | 1 | 0.16 |
Physical Sciences | 2 | 0.23 |
Share output for the past 5 years
2016 | 2017 | 2018 | 2019 | 2020 |
---|---|---|---|---|
43.91 | 54.75 | 57.50 | 47.80 | 59.77 |
Collaboration
Date range: 1 May 2021 - 30 April 2022
International vs. domestic collaboration by Share
- 7.03% Domestic
- 92.97% International
Hover over the graph to view the percentage of collaboration.
Top 10 domestic collaborators with F. Hoffmann-La Roche AG by Share (19 total)
-
F. Hoffmann-La Roche AG and Swiss Federal Institute of Technology Lausanne (EPFL)
(3.37)
-
F. Hoffmann-La Roche AG and University of Lausanne (UNIL)
(2.93)
-
F. Hoffmann-La Roche AG and University of Basel (UB)
(2.34)
-
F. Hoffmann-La Roche AG and Swiss Federal Institute of Technology Zurich (ETH Zurich)
(1.40)
-
F. Hoffmann-La Roche AG and Swiss Institute of Bioinformatics (SIB)
(1.31)
-
F. Hoffmann-La Roche AG and AC Immune S.A.
(0.98)
-
F. Hoffmann-La Roche AG and LICR Lausanne Branch
(0.75)
-
F. Hoffmann-La Roche AG and Università della Svizzera Italiana (USI)
(0.70)
-
F. Hoffmann-La Roche AG and University of Bern (UniBE)
(0.45)
-
F. Hoffmann-La Roche AG and Swiss Tropical and Public Health Institute (Swiss TPH)
(0.38)
Top 10 international collaborators with F. Hoffmann-La Roche AG by Share (1070 total)
-
F. Hoffmann-La Roche AG and Harvard University
(6.41)
-
F. Hoffmann-La Roche AG and University of California, San Francisco (UCSF)
(5.31)
-
F. Hoffmann-La Roche AG and University of California, San Diego (UC San Diego)
(4.26)
-
F. Hoffmann-La Roche AG and Stanford University
(3.61)
-
F. Hoffmann-La Roche AG and Mount Sinai Health System (MSHS)
(3.35)
-
F. Hoffmann-La Roche AG and Columbia University in the City of New York (CU)
(2.52)
-
F. Hoffmann-La Roche AG and Queen Mary University of London (QMUL)
(2.41)
-
F. Hoffmann-La Roche AG and Foundation Medicine, Inc.
(2.36)
-
F. Hoffmann-La Roche AG and Max Planck Society
(2.32)
-
F. Hoffmann-La Roche AG and Broad Institute of MIT and Harvard
(2.20)
Relationships
F. Hoffmann-La Roche AG
- 454 Life Sciences
- Anadys Pharmaceuticals, Inc.
- Ariosa Diagnostics, Inc.
- Bina Technologies, Inc.
- Chugai Pharmaceutical Co., Ltd.
- F. Hoffmann-La Roche Ltd.
- Flatiron Health, Inc.
- Genentech, Inc.
- Genia Corporation
- Hoffmann-La Roche Ltd.
- Hoffmann-La Roche, Inc.
- InterMune, Inc.
- Piramed Ltd.
- Roche Deutschland Holding GmbH
- Roche Diabetes Care IT
- Roche Diagnostics Asia Pacific Pte Ltd.
- Roche Diagnostics Corporation
- Roche Diagnostics S.L.
- Roche Farma, S.A.
- Roche Molecular Systems, Inc.
- Roche Nederland B.V.
- Roche NimbleGen, Inc.
- Roche Nutley
- Roche Palo Alto, LLC
- Roche Pharmaceuticals - Poland
- Roche Products Limited
- Roche R&D Center (China) Ltd.
- Roche S.A.S
- Roche Sequencing Solutions (RSS)
- Ventana Medical Systems, Inc.
Affiliated joint institutions and consortia

Numerical information only is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.